Clinton E. Leysath - Concepedia

Concepedia

Author

Clinton E. Leysath

National Institutes of Health

Also Known As

C E Leysath, C. Leysath, C.E. Leysath, Clinton E. Leysath, Clinton Leysath

25

Publications

1.3K

Citations

16

H-Index

46

Concepts

All Affiliations

National Institutes of Health National Institute of Allergy and Infectious Diseases The University of Texas MD Anderson Cancer Center New England Disabled Sports The University of Texas at Austin

CE

About

Clinton E. Leysath is an author at National Institutes of Health specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	502
2	Natural Sciences	2	2	138
3	Engineering	1	1	32
4	Allergy	1	1	11
5	Biochemistry	1	1	36

Clinton E. Leysath

×

20

Publications

1.3K

Citations

16

H-Index

	Year	Citations
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells Linhua Jin, Yoko Tabe, Sergej Konoplev, Molecular Cancer Therapeutics Mixed-phenotype Acute LeukemiaImmunologyCxcr4 LevelsCxcr4 ExpressionTumor Biology	2008	204
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia Marina Konopleva, Twee Tsao, Peter P. Ruvolo, Blood	2002	189
The sub‐nanomolar binding of DNA–RNA hybrids by the single‐chain Fv fragment of antibody S9.6 Damilola D. Phillips, David N. Garboczi, Kavita Singh, Journal of Molecular Recognition	2013	159
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia Michèle Milella, Zeev Estrov, Steven M. Kornblau, Blood	2002	119
A Single VHH-Based Toxin-Neutralizing Agent and an Effector Antibody Protect Mice against Challenge with Shiga Toxins 1 and 2 Jacqueline M. Tremblay, Jean Mukherjee, Clinton E. Leysath, Infection and Immunity ToxinologyImmunologyAnalytical UltracentrifugationImmunotherapyToxicological Mechanism	2013	102
A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model Jean Mukherjee, Jacqueline M. Tremblay, Clinton E. Leysath, PLoS ONE	2012	90
Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2) Phillip A. Morton, X T Fu, James A. Stewart, The Journal of Immunology	1996	76
Engraftment of Acute Myeloid Leukemia in NOD/SCID Mice Is Independent of CXCR4 and Predicts Poor Patient Survival Giuseppe Monaco, Marina Konopleva, Mark F. Munsell, Stem Cells Hematological MalignancyCell TherapyCxcr4 ExpressionAcute Myeloid LeukemiaMalignant Blood Disorder	2004	48
Engineering Anthrax Toxin Variants That Exclusively Form Octamers and Their Application to Targeting Tumors Damilola D. Phillips, Rasem Fattah, Devorah Crown, Journal of Biological Chemistry	2013	44
A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model Mahtab Moayeri, Clinton E. Leysath, Jacqueline M. Tremblay, Journal of Biological Chemistry	2015	39

Page 1